SPIRE-2 (Completed)
The Evaluation of Bococizumab (PF-04950615) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2)
- Medicine
- Bococizumab
- Population
- ASCVD
- Phase
- III
- Starting year
- 2014
- More information
- ClinicalTrials.gov